First National Trust Co. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 120,976 shares of the company’s stock after purchasing an additional 2,024 shares during the quarter. Johnson & Johnson accounts for 1.8% of First National Trust Co.’s holdings, making the stock its 7th largest position. First National Trust Co.’s holdings in Johnson & Johnson were worth $15,728,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Harding Loevner LP bought a new position in Johnson & Johnson in the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the second quarter valued at approximately $124,000. Shine Investment Advisory Services Inc. bought a new position in Johnson & Johnson in the second quarter valued at approximately $177,000. Finally, Lenox Wealth Management Inc. increased its stake in Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after acquiring an additional 24 shares during the last quarter. 65.70% of the stock is currently owned by institutional investors.
A number of research analysts recently issued reports on the stock. BMO Capital Markets reissued a “positive” rating and issued a $152.00 price objective (up from $145.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Jefferies Group lifted their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday, October 18th. Leerink Swann reissued an “outperform” rating and issued a $165.00 price objective (up from $150.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Finally, Wells Fargo & Co reissued an “outperform” rating and issued a $155.00 price objective (up from $149.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, eight have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $146.16.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The firm had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same quarter last year, the business posted $1.58 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis. equities research analysts expect that Johnson & Johnson will post 8.08 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.59%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 861.54%.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/02/10/first-national-trust-co-increases-stake-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.